1. Amin, MB , American Joint Committee on Cancer and American Cancer Society (eds). AJCC cancer staging manual. 8th ed. (editor-in-chief, Mahul B. Amin, MD, FCAP; editors, Stephen B. Edge, MD, FACS [and 16 others]; Donna M. Gress, RHIT, CTR-Technical editor; Laura R. Meyer, CAPM-Managing editor). Berlin: American Joint Committee on Cancer, Springer, 2017.
Google Scholar | Crossref2. Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. doi:10.3322/caac.21492.
Google Scholar | Crossref | Medline3. Nagtegaal, ID, Odze, RD, Klimstra, D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182-188.
Google Scholar | Crossref | Medline4. Siegel, RL, Miller, KD, Goding Sauer, A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145-164.
Google Scholar | Crossref | Medline5. Ferlay, J, Colombet, M, Soerjomataram, I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356-387.
Google Scholar | Crossref | Medline6. Mesker, WE, Junggeburt, JMC, Szuhai, K, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol. 2007;29:387-398.
Google Scholar | Medline7. Zunder, SM, Gelderblom, H, Tollenaar, RA, Mesker, WE. The significance of stromal collagen organization in cancer tissue: an in-depth discussion of literature. Crit Rev Oncol Hematol. 2020;151:102907.
Google Scholar | Crossref | Medline8. Ribeiro Franco, PI, Rodrigues, AP, de Menezes, LB, Pacheco Miguel, M. Tumor microenvironment components: allies of cancer progression. Pathol Res Pract. 2020;216:152729.
Google Scholar | Crossref | Medline9. Scheer, R, Baidoshvili, A, Zoidze, S, et al. Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: a retrospective cohort study. World J Gastrointest Oncol. 2017;9:466-474. doi:10.4251/wjgo.v9.i12.466.
Google Scholar | Crossref | Medline10. Wu, J, Liang, C, Chen, M, Su, W. Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis. Oncotarget. 2016;7:68954-68965.
Google Scholar | Crossref | Medline11. Ao, T, Kajiwara, Y, Yonemura, K, et al. Morphological consistency of desmoplastic reactions between the primary colorectal cancer lesion and associated metastatic lesions. Virchows Arch. 2020;477:47-55.
Google Scholar | Crossref | Medline12. Park, JH, Richards, CH, McMillan, DC, Horgan, PG, Roxburgh, CSD. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol. 2014;25:644-651.
Google Scholar | Crossref | Medline13. Huijbers, A, Tollenaar, RAEM, Pelt, GWV, et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol. 2013;24:179-185. doi:10.1093/annonc/mds246.
Google Scholar | Crossref | Medline14. van Pelt, GW, Kjær-Frifeldt, S, van Krieken, JHJM, et al. Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. Virchows Arch. 2018;473:405-412.
Google Scholar | Crossref | Medline15. Abstracts: 31st European Congress of Pathology . Virchows Arch. 2019;475:1-436.
Google Scholar | Medline16. Mesker, WE, Liefers, G-J, Junggeburt, JMC, et al. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol. 2009;31:169-178.
Google Scholar | Medline17. van Pelt, GW, Hansen, TF, Bastiaannet, E, et al. Stroma-high lymph node involvement predicts poor survival more accurately for patients with stage III colon cancer. J Med Surg Pathol. 2016;1:1000116. doi:10.4172/2472-4971.1000116.
Google Scholar | Crossref | Medline18. de Kruijf, EM, van Nes, JG, van de Velde, CJ, et al. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat. 2011;125:687-696.
Google Scholar | Crossref | Medline19. Dekker, TJA, van de Velde, CJ, van Pelt, GW, et al. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res Treat. 2013;139:371-379.
Google Scholar | Crossref | Medline20. Roeke, T, Sobral-Leite, M, Dekker, TJA, et al. The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study. Breast Cancer Res Treat. 2017;166:435-445.
Google Scholar | Crossref | Medline21. Courrech Staal, EF, Wouters, MW, van Sandick, JW, et al. The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer. 2010;46:720-728.
Google Scholar | Crossref | Medline22. West, NP, Dattani, M, McShane, P, et al. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer. 2010;102:1519-1523. doi:10.1038/sj.bjc.6605674.
Google Scholar | Crossref | Medline23. Wang, K, Ma, W, Wang, J, et al. Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. J Thorac Oncol. 2012;7:1457-1461.
Google Scholar | Crossref | Medline24. Moorman, AM, Vink, R, Heijmans, HJ, van der Palen, J, Kouwenhoven, EA. The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur J Surg Oncol. 2012;38:307-313. doi:10.1016/j.ejso.2012.01.002.
Google Scholar | Crossref | Medline25. Wang, Z, Liu, H, Zhao, R, Zhang, H, Liu, C, Song, Y. [Tumor-stroma ratio is an independent prognostic factor of non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi. 2013;16:191-196.
Google Scholar | Medline26. Zhang, X-L, Jiang, C, Zhang, Z-X, Liu, F, Zhang, F, Cheng, Y-F. The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer. Oncol Res Treat. 2014;37:480-484.
Google Scholar | Crossref | Medline27. Gujam, FJA, Edwards, J, Mohammed, ZMA, Going, JJ, McMillan, DC. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Br J Cancer. 2014;111:157-165.
Google Scholar | Crossref | Medline28. Liu, J, Liu, J, Li, J, et al. Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma. Gynecol Oncol. 2014;132:81-86.
Google Scholar | Crossref | Medline29. Lv, Z, Cai, X, Weng, X, et al. Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. Surgery. 2015;158:142-150.
Google Scholar | Crossref | Medline30. Chen, Y, Zhang, L, Liu, W, Liu, X. Prognostic significance of the tumor-stroma ratio in epithelial ovarian cancer. Biomed Res Int. 2015;2015:589301.
Google Scholar | Crossref | Medline31. Pongsuvareeyakul, T, Khunamornpong, S, Settakorn, J, et al. Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. Asian Pac J Cancer Prev. 2015;16:4363-4368.
Google Scholar | Crossref | Medline32. Li, H, Yuan, SL, Han, ZZ, et al. Prognostic significance of the tumor-stroma ratio in gallbladder cancer. Neoplasma. 2017;64:588-593.
Google Scholar | Crossref | Medline33. Landis, JR, Koch, GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977;33:363-374.
Google Scholar | Crossref | Medline34. Hansen, TF, Kjær-Frifeldt, S, Lindebjerg, J, et al. Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. Acta Oncol. 2018;57:528-533.
Google Scholar | Crossref | Medline